Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
George, Daniel J.
Sternberg, Cora N.
Sartor, A. Oliver
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Higano, Celestia S.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[3] Tulane Med Sch, New Orleans, LA USA
[4] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Clin Univ St Luc, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (vol 16, e0253021, 2021)
    Kim, Stephanie I.
    Szeto, Andy H.
    Morgan, Katherine P.
    Brower, Blaine
    Dunn, Mary W.
    Khandani, Amir H.
    Godley, Paul A.
    Rose, Tracy L.
    Basch, Ethan M.
    Milowsky, Matthew I.
    Whang, Young E.
    Crona, Daniel J.
    PLOS ONE, 2021, 16 (12):
  • [42] Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience
    Poon, Darren M. C.
    Chan, Kuen
    Lee, S. H.
    Chan, T. W.
    Sze, Henry
    Lee, Eric K. C.
    Lam, Daisy
    Chan, Michelle F. T.
    BMC UROLOGY, 2016, 16
  • [43] Real-world patterns of genomic testing in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Shore, N.
    Ionescu-Ittu, R.
    Yang, L.
    Laliberte, F.
    Payne, S.
    Gayle, A.
    Amin, S.
    Mahendran, M.
    Lejeune, D.
    Yu, L.
    Burgents, J.
    Duh, M. S.
    Ghate, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S526 - S527
  • [44] Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
    Prelaj, Arsela
    Rebuzzi, Sara Elena
    Buzzacchino, Federica
    Pozzi, Chiara
    Ferrara, Carla
    Frantellizzi, Viviana
    Follacchio, Giulia Anna
    Civitelli, Liana
    De Vincentis, Giuseppe
    Tomao, Silverio
    Bianco, Vincenzo
    ONCOLOGY LETTERS, 2019, 17 (02) : 1467 - 1476
  • [45] Outcomes with Radium-223 therapy in clinical practice of metastatic castration resistant prostate cancer (mCRPC).
    Alva, Ajjai Shivaram
    Nordquist, Luke T.
    Daignault, Stephanie
    George, Saby
    Ramos, Jorge
    Isharwal, Sudhir
    McDonald, Matthew
    Campbell, Gregory
    Danchaivijitr, Pongwut
    Albany, Costantine
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience
    Peters, Niamh
    Gaffney, John
    Connolly, Emma
    Bambury, Richard
    Power, Derek Gerard
    Kelly, Paul J.
    Jamaluddin, Muhammad Faisal
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [47] Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry
    Kuppen, M. C. P.
    Westgeest, H. M.
    van den Eertwegh, A. J. M.
    Van Moorselaar, J.
    Mehra, N.
    Coenen, J. L.
    van Oort, I.
    van den Bergh, A. C. M.
    Lavalaye, J.
    Aben, K. K. H.
    Somford, D. M.
    de Wit, R.
    Bergman, A. M.
    Uyl-de Groot, C.
    Gerritsen, W. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Use of Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer
    Parker, Chris
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (11) : 723 - 725
  • [49] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [50] Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
    Shore, Neal
    Carles, Joan
    McDermott, Ray
    Agarwal, Neeraj
    Tombal, Bertrand
    FRONTIERS IN MEDICINE, 2024, 11
12345